Stay updated on Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial
Sign up to get notified when there's something new on the Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial page.

Latest updates to the Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedAdded a Locations section with California listed and updated the page revision from v3.3.2 to v3.3.3.SummaryDifference0.2%

- Check24 days agoNo Change Detected
- Check38 days agoChange DetectedThe page shows a revision update from v3.3.1 to v3.3.2; there is no change to the study content, eligibility, endpoints, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check45 days agoChange DetectedPublication notes now indicate that PubMed publications are automatically filled from PubMed and may not be about the study, and the revision label has been updated to v3.3.1 from v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check53 days agoChange DetectedRemoval of the funding/operational status notice; the page continues to display the study details, eligibility criteria, and study plan.SummaryDifference0.4%

- Check67 days agoChange DetectedThe update shows revised last update timestamps and minor layout adjustments; core study details (title, conditions, eligibility criteria, and outcomes) are unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check95 days agoChange DetectedUpdate introduces version v3.2.0 and a government-operating status notice; it also removes the genetic resource for B-cell chronic lymphocytic leukemia.SummaryDifference5%

Stay in the know with updates to Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial page.